Bromoxanide

This classification denotes an antihelminthic agent with the molecular formula C19H18BrF3N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9MM438AA0G, chemically known as 4-bromo-3-tert-butyl-alpha,alpha,alpha-trifluoro-5-nitro-2,6-cresoto-o-toluidide but generally known as bromoxanide, which bears US NIH Compound Identifier 166570. European Medicines Agency schedules Bromoxanide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05922MIG. The term BROMOXANIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). BROMOXANIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bromoxanide under HS 29242995 and SITC 51479. As of Q4 2014, BROMOXANIDE remains the US FDA Preferred Term for this commodity. Bromoxanide bears US NLM identifiers UMLS ID C2347217 and NCI Concept Code C72148. SMILES: BRC1CC(C(NC(=O)C2C(O)C(C(C)(C)C)CC([N](=O)O)C2C)CC1)C(F)(F)F.